Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 12/20 | 0.73 |
| ▸ | MEN1 | O00255 | 9/20 | 0.73 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | ATM | Q13315 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | MITF | O75030 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALPG | P10696 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 2/20 | 0.44 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL5257467 | 0.85 | KMT2A (1.00) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL6228650 | 0.84 | KMT2A (1.00) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL5260112 | 0.84 | KMT2A (1.00) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30636590 | 0.82 | KMT2A (0.97) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1128535 | 0.82 | KMT2A (0.97) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18320467 | 0.77 | KMT2A (0.85) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL30686948 | 0.77 | KDM4E (1.00) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL27074266 | 0.77 | KDM4E (1.00) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL5260393 | 0.76 | KMT2A (0.81) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL5256821 | 0.74 | KMT2A (0.65) | KMT2AMEN1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578424-A4 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CASP3, CASP7, CASP1 | KMT2A 1411/4885MEN1 2503/4885KDM4E 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.